Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company based in Morristown, New Jersey, has announced a significant milestone in its journey by successfully completing its transition to the OTCQB Venture Market as of June 25, 2025. This transition marks the beginning of trading under the ticker symbol HEPA on the OTCQB, which is designed for early-stage and growth companies looking for access to the public market.

Hepion Pharmaceuticals is engaged in the development and commercialization of crucial diagnostic tests that cater to various health concerns, including celiac disease, respiratory multiplex (which covers Covid-19, Influenza A/B, and RSV), as well as testing for helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). These tests are vital, especially as they address high-priority medical conditions and contribute to enhancing patient care.

Transitioning to the OTCQB will provide Hepion with a broader platform to increase visibility and attract more investors, which is essential for a clinical-stage company. The OTCQB is known for offering a transparent trading environment, making it a suitable choice for companies like Hepion that are still establishing themselves in the biopharmaceutical space.

Hepion's commitment to developing innovative diagnostic solutions underscores its role in addressing significant health challenges, particularly in the current landscape influenced by the ongoing pandemic and related respiratory illnesses. The successful shift to OTCQB could potentially enhance the company's funding opportunities and investor engagement, aiding in the advancement of its clinical programs.

For further inquiries or more detailed information about Hepion Pharmaceuticals, interested parties are encouraged to contact the company directly at info@hepionpharma.com.

Hepion Pharmaceuticals, Inc. (OTCQB: HEPA), recently announced its successful transition to the OTCQB Venture Market, marking a significant milestone for the company and its stakeholders. The transition to OTCQB not only enhances Hepion’s visibility and credibility but also broadens its access to capital, which is crucial for a clinical-stage biopharmaceutical firm focused on developing innovative diagnostic tests for several serious health conditions.

Investors should view this transition as a positive indicator, as the OTCQB listings require companies to meet certain standards, including financial disclosures and reporting obligations, that can help instill greater investor confidence. Hepion's focus on diagnostics for conditions like celiac disease, respiratory infections (including COVID-19), and hepatocellular carcinoma positions the company in key healthcare markets that are witnessing growing demand.

Market interest in healthcare and biopharmaceutical investments has been robust, particularly in the aftermath of the pandemic; thus, Hepion's initiatives align well with current market trends. However, potential investors should remain cognizant of the inherent risks associated with biopharmaceutical companies, particularly those still in clinical stages, as they may face long development timelines and significant regulatory hurdles before achieving commercialization.

Given its specialized focus and newly acquired OTCQB listing, Hepion Pharmaceuticals may present an attractive opportunity for investors interested in the growing field of diagnostics. It is essential for investors to conduct thorough due diligence, considering both the promising aspects of Hepion’s technology and the broader market dynamics that influence biopharmaceutical stock performance. Diversifying within the healthcare sector and keeping an eye on Hepion’s future developments, clinical trials, and financial health will be key strategies as the company embarks on this new chapter of growth.